U.S. Markets closed
  • S&P Futures

    3,448.50
    +16.25 (+0.47%)
     
  • Dow Futures

    28,296.00
    +114.00 (+0.40%)
     
  • Nasdaq Futures

    11,722.50
    +61.75 (+0.53%)
     
  • Russell 2000 Futures

    1,621.20
    +6.40 (+0.40%)
     
  • Crude Oil

    41.51
    +0.05 (+0.12%)
     
  • Gold

    1,922.90
    +7.50 (+0.39%)
     
  • Silver

    25.18
    +0.20 (+0.80%)
     
  • EUR/USD

    1.1846
    +0.0017 (+0.1421%)
     
  • 10-Yr Bond

    0.7970
    +0.0360 (+4.73%)
     
  • Vix

    29.35
    +0.17 (+0.58%)
     
  • GBP/USD

    1.2968
    +0.0022 (+0.1673%)
     
  • USD/JPY

    105.3760
    -0.0940 (-0.0891%)
     
  • BTC-USD

    12,022.48
    +965.47 (+8.73%)
     
  • CMC Crypto 200

    241.39
    +2.47 (+1.03%)
     
  • FTSE 100

    5,889.22
    +4.57 (+0.08%)
     
  • Nikkei 225

    23,673.14
    +106.10 (+0.45%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Odonate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 16, 2020 - ODT

Newsfile Corp.
·2 mins read

New York, New York--(Newsfile Corp. - September 23, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Odonate Therapeutics, Inc. ("Odonate") (NASDAQ: ODT) between December 7, 2017 and April 21, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Southern District of New York. To get more information go to:

https://www.zlk.com/pslra-1/odonate-therapeutics-inc-information-request-form?prid=9556&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company's orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel's commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you suffered a loss in Odonate you have until November 16, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64530